Background {#Sec1}
==========

*Shigella* are Gram-negative bacteria that represent the etiologic agent of the shigellosis, a global human health problem, especially in developing countries and in children younger than 5 years. Shigellosis is estimated to cause annually 125 million cases and 100,000 deaths \[[@CR1]\], and is one of main causes of traveller's diarrhea. The genus *Shigella* comprises four serogroups (*Shigella dysenteriae*, *Shigella sonnei*, *Shigella flexneri* and *Shigella boydii*) subdivided in 50 different serotypes based on the carbohydrate composition of the O antigen of their lipopolysaccharide \[[@CR2]\] and the presence of serotypes varies among different regions and over time \[[@CR3]\]. As no vaccines are currently widely available, one of the aims of the European Union-funded STOPENTERICS consortium (Vaccination against *Shigella* and ETEC: novel antigens, novel approaches) \[[@CR4]\] is to develop novel vaccine candidates against *Shigella* \[e.g. the Generalized Modules for Membrane Antigens (GMMA) approach \[[@CR5], [@CR6]\]\], as well as to improve the immunogenicity of the existing antigens (e.g. synthetic chemistry for glycoconjugates \[[@CR7]\]). To this end, partners of the STOPENTERICS consortium have been integrating basic research, particularly genomics, transcriptomics, proteomics, and other high-throughput technologies, with novel vaccine technologies and synthetic chemistry \[[@CR7]\]. To assemble *Shigella* expertise to identify and rapidly take novel vaccine candidates through to clinical trials for effective vaccine development, the research is carried out among different academic institutions (e.g. University of Oxford, Wellcome Trust Sanger Institute, Institut Pasteur) and vaccines companies (Novartis Vaccines Institute for Global Health and Sanofi-Pasteur).

To ensure the congruence of strains between laboratories, and create a public resource for vaccine development and further *Shigella* research, we whole genome sequenced the *Shigella* strains used by the STOPENTERICS consortium which are used as they offer most effective breadth of cross-protection against *Shigella* sp. in endemic areas \[[@CR8]\], and report the assembly and annotation of their draft genomes. We assessed the presence of SNPs between strains and against references, as well as defined their phylogenetic relationships, and compared genetic stability of strains maintained in different consortium laboratories and after serial passage.

Methods {#Sec4}
=======

Bacterial strains {#Sec10}
-----------------

The *Shigella* strains analysed in this study and relevant metadata are summarized in Table [1](#Tab1){ref-type="table"}. Strains were serotyped by slide agglutination using commercially available monovalent antisera (Denka Seiken, Japan) to all type specific somatic antigens and the group factor antigens \[[@CR9]\].

DNA extraction and genome sequencing {#Sec11}
------------------------------------

Bacterial cultures were grown over night in liquid Luria--Bertani (LB) media to an optical density (measured at 600 nm) of approximately three. Genomic DNA was isolated using the Wizard kit (Promega, Madison, WI, USA) according to manufacturer's instructions. Purified DNA was then sequenced at the Wellcome Trust Sanger Institute (WTSI). Paired end libraries 150 bp in length were generated and sequenced on the Illumina MiSeq instrument (San Diego, CA, USA) according to in house protocols \[[@CR10], [@CR11]\], with an approximately 500 bp insert size. Sequence data for each of the strains were deposited in the European Nucleotide Archive (accession numbers in Table [1](#Tab1){ref-type="table"}).

Genomic analysis {#Sec12}
----------------

Resulting sequencing reads were trimmed using Trimmomatic v0.27 \[[@CR12]\] to remove adapters, bases with a PHRED score of \<30, and remaining reads with lengths \<50 bp.

High quality reads were then mapped to relevant reference strains (Table [1](#Tab1){ref-type="table"}), using SMALT (<http://www.sanger.ac.uk/resources/software/smalt/>) and Single Nucleotide Polymorphisms (SNPs) were called using Samtools \[[@CR13]\]. Nucleotides where mapping quality was below 30 and genotyping quality was below 50 were excluded from further analysis. Mapping coverage of all isolates was approximately 70-fold coverage.

De novo assembly was performed using Velvet Optimiser \[[@CR14]\] and contiguous sequences were annotated using Prokka \[[@CR15]\]. Clustering and BLAST comparisons were used to determine the presence/absence of genes in annotated assemblies as previously described \[[@CR16]\].

To prepare a multiple sequence alignment for phylogenetic analysis, sequencing data from strains in this study and from simulated fastq data created from published reference genomes were mapped to the chromosome of *S. flexneri* 2457T (GenBank accession: NC_004741.1). The other reference isolates (and their accessions) used in this analysis were: *S. sonnei* Ss046 (NC_007384.1), *S. sonnei* 53G (NC_016822.1), *S. flexneri* 5 M90T (AGNM01000000), *S. flexneri* 5a 8401 (NC_008258.1), *S. flexneri* 2a NCTC1 (LM651928), *S. flexneri* 2a 301 (NC_004337.2), *S. flexneri* X 2002017 (NC_017328.1) and *S. boydii* Sb 227 (NC_007613.1). Core genes (n = 2,427) were identified that had 100% mapping coverage in all isolates and phylogenetic analysis was performed using RAxML software v7.0.3 \[[@CR17]\] on the 43,349 variable sites (subset from 2,306,256 bp) of these core genes.

In silico molecular serotyping of *S. flexneri* isolates was performed on de novo assemblies for each isolate (and as in \[[@CR18]\]). Briefly, the presence/absence and known differences of the *gtr* genes (encoding for enzymes responsible of the presence of type specific antigens I, II, IV, V, X, IC), *oac* genes (encoding for enzymes that mediates O-acetylation modification in serotypes 1b, 3a, 3b, and 4b) and *wzx*6 (specific for serotype 6) were analyzed, facilitating the differentiation of the six different *S. flexneri* serotypes.

Results and discussion {#Sec2}
======================

Sixteen different *Shigella* isolates belonging to seven different serotypes were sequenced (listed in Table [1](#Tab1){ref-type="table"}). These included *S. sonnei* (2 isolates) and different *S. flexneri* serotypes including 1a, 1b (2 isolates), 2a, 3a, 5a and 6 (eight different isolates) plus four derivative strains from either serial passage (*S. sonnei* 53G, *S. flexneri* 2a 2457T) or having been cultivated and the DNA extracted in different laboratories (*S.* *flexneri* 3a 6865 and *S. flexneri* 6 10.5302). Derivative strains from the same isolate, but manipulated in different laboratories of the STOPENTERICS consortium were denoted '\_1' and '\_2', whereas those that had undergone serial passage (\~10 passages) in the same laboratory were denoted '\_p'. The derivatives allowed us to assess the genetic stability of strains across laboratories and through serial passage.Table 1Summary results assembly, annotation and mappingName in the studyTrue name, country of infection, year of isolationSample run accessionSample accessionDe novo assembly genomic sizeContigs numberAverage Contigs LengthN50CDS detectedReference used for mappingNumber of SNPs detected% of reference mappedSs_53GKorea, 2000ERS387232ERR4773764,698,81440211,688.5929,8564,495Ss 53G292.86Ss_53G_pKorea, 2000ERS387243ERR4773874,832,55940611,902.8528,1774,655Ss 53G292.80Ss_25931UnknownERS387235ERR4773794,799,85242611,267.2627,7654,578Ss 53G63089.51Sf 1a_Sh07.3008Sh07-3008, Cameroon, 2007ERS445026ERR5733824,139,08026515,619.1734,7714,044Sf 2a 2457T3,45986.58Sf 1b_Sh04.7434Sh04-7432, Tunisia, 2004ERS445024ERR5733804,402,07831414,019.3634,5524,342Sf 2a 2457T2,93587.63Sf 1b_Sh04.9462Sh04-9462, Cameroon, 2004ERS445025ERR5733814,272,35828015,258.4234,7564,206Sf 2a 2457T3,20787.36Sf 2a_2457TJapan, 1954ERS387233ERR4773774,681,42934413,608.8135,4414,583Sf 2a 2457T19593.72Sf 2a_2457T_pJapan, 1954ERS387242ERR4773864,697,21134313,694.4935,1514,605Sf 2a 2457T19293.88Sf 3a_6865_1UnknownERS387236ERR4773804,665,09933513,925.6735,4954,550Sf 2a 2457T7,54386.79Sf 3a_6865_2UnknownERS445023ERR5733794,704,03033014,254.6435,9914,580Sf 2a 2457T7,70887.08Sf 5a_M90TUnknown \<1980ERS387234ERR4773784,486,89932713,721.4032,1604,391Sf 5a M90T2597.82Sf 6_Sh10.5302_1201005302, Madagascar, 2010ERS387237ERR4773814,414,1464469,897.1922,8384,269Sb Sb2274,40889.30Sf 6_Sh10.5302_2201005302, Madagascar, 2010ERS445029ERR5733854,351,33642610,214.422,7744,168Sb Sb2274,40689.10Sf 6_Sh10.3933201003933, Nigeria, 2010ERS387238ERR4773824,508,36843310,411.9423,0904,386Sb Sb2274,45689.33Sf 6_Sh10.8537201008537, Egypt, 2010ERS387239ERR4773834,524,54742510,645.9923,2384,398Sb Sb2274,45189.77Sf 6_Sh10.6306201006306, India, 2010ERS387240ERR4773844,481,17843910,207.6923,0664,367Sb Sb2274,46789.44Sf 6_Sh10.6237201006237, Mexico, 2010ERS387241ERR4773854,528,96843410,435.4124,0124,397Sb Sb2274,38989.39Sf 6_NCDC.2924-71NCDC 2924-71, Unknown, 1971ERS445027ERR5733834,392,20841310,634.8922,7844,246Sb Sb2274,28889.66Sf 6_Sc544Unknown, \<1977ERS445028ERR5733844,430,66741510,676.3122,4944,302Sb Sb2274,29688.82Sf 6_Sh11.10088201110088, France (Reunion Island), 2011ERS445030ERR5733864,547,25642310,750.0123,9914,428Sb Sb2274,48389.88

Results of genomic assembly and annotation were similar for all strains (Table [1](#Tab1){ref-type="table"}). The strains assembled into an average of 381 contigs (range 265--446), with an average contigs length of 12,141 bp (range 9,897--15,619) and an N50 of 28,620 (range 22,494--35,991). The resulting genomic size was similar for all the strains and fell within the range of 4.14--4.83 Mbp. Similarly, automated annotation predicted the presence of an average of 4,400 coding sequences per genome (range 4,044--4,583; Table [1](#Tab1){ref-type="table"}). The serotypes of the *Shigella* strains were confirmed based on the combinations of *gtr* and *oac* genes, encoding the relevant enzymes for the serotype-specific OAg modifications \[[@CR18]\] (not shown).

To facilitate strain comparisons and phylogenetic analysis, sequence reads were mapped to existing *Shigella* reference genomes (Table [1](#Tab1){ref-type="table"}). The percentage of the reference genome covered by mapped reads ranged from 87 to 98% and the number of SNPs varied (Table [1](#Tab1){ref-type="table"}) depending on the isolate. These data showed comparatively few SNPs (\<200) when an isolate was compared to a previously published reference of itself (as in the case of *S. sonnei* 53G, *S. flexneri* 2a 2457T, *S.* *flexneri* 5a M90T). Higher numbers of SNPs were seen where no such reference was available. For example, when an isolate was mapped to a reference genome of a different isolate of the same serotype (e.g. Ss_25931 mapped against Ss_53G) several hundred SNPs were seen, and several thousand SNPs were seen if the isolate was mapped to a reference isolate from a phylogenetic related, but distinct serotype (e.g. *S. flexneri* six isolates mapped against *S. boydii* strain Sb227).

To assess the genomic stability of isolates held at different laboratories and through serial passage within the same laboratory, we resequenced a number of isolates and compared their mapping results to the relevant reference (Table [1](#Tab1){ref-type="table"}). Two isolates (original and passaged) of *S. sonnei* 53G had only two SNPs relative to the published reference genome, and these SNPs were the same in both isolates. Similarly, the sequences of original and passaged *S. flexneri* 2a strain 2457T were very similar, but had 195 and 192 SNPs relative to the published reference genome. Among these SNPs, 188 were common to both isolates and the remaining four and seven sites were not resolved in the other isolate, indicating that the two isolates were likely identical to each other. The level of genetic variation compared to the reference strain was surprising (\~200 SNPs) and may have biological significance, showing the utility of obtaining up-to-date genetic information for the exact strain being worked with in a given project. Two strains, Sf 3a_6865 and Sf 6_10.5302, were manipulated for sequencing in separate laboratories in the consortium. These strains differed by only one and two SNPs respectively, indicating that over a 2--3 year time period, isolate genomes remain relatively stable through passage and between laboratories, but may differ significantly from published references.

To assess the phylogenetic relationship of the isolates, we constructed a maximum likelihood phylogenetic tree of a large core genome shared among the strains (Figure [1](#Fig1){ref-type="fig"}). Consistent with expectations based on prior evolutionary studies of shigellae \[[@CR19], [@CR20]\], the strains were divided into three main clades, with the *S. flexneri* six strains being phylogenetically removed from the remaining *S. flexneri* serotypes, and the *S. sonnei* strains forming a separate clade.Figure 1Mid-point rooted maximum likelihood phylogeny of strains based on core genome. Names of strains sequenced in this study are abbreviated and those of reference genomes are given in full.

Conclusions {#Sec3}
===========

The work presented here increases the number of publically available *Shigella* genomes, including for the first time, sequencing data for *S. sonnei* 25931, two *S. flexneri* 1b, one *S. flexneri* 1a, one *S. flexneri* 3a and 8 *S. flexneri* six isolates. We provide details on the draft genomes generated from this sequencing data, and report SNP variation in strains maintained in different laboratories and after serial passage. We also described the relatedness of the strains and isolates used by the STOPENTERICS consortium, and have deposited this data as a public resource. Data presented in this work will guide the selection of strains for further development of vaccine and contribute to a growing awareness of diversity in *Shigella*.
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